Health and Me on MSN6h
FDA Approves Qfitlia For Hemophilia PatientsThe approval came on the basis of two randomized clinical trials that had 177 adult and pediatric male patients with either ...
The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or ...
The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...
Qfitlia does not replace the missing clotting factor. Rather, it reduces the amount of a protein called antithrombin, leading ...
Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII (FVIII) or IX (FIX), respectively. Patients with these hemophilias are ...
Alhemo prophylaxis is linked to better quality of life and a lower treatment burden for hemophilia patients without ...
The firm's Innovance Antithrombin assay is used to monitor antithrombin activity levels in hemophilia patients and aid dosing decisions for a routine prophylaxis.
The antithrombin assay will support dosing Qfitlia, the sixth Alnylam-discovered RNAi medicine to receive FDA approval.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback